Idarubicin and cytosine arabinoside reinduction therapy for children with multiple recurrent or refractory acute lymphoblastic leukemia: A pediatric oncology group study

Keyphrases

• Acute Lymphoblastic Leukemia 100%
• Group Studies 100%
• Idarubicin 100%
• Pediatric Oncology 100%
• Cytosine Arabinoside 100%
• Reinduction Therapy 100%
• Bone Marrow Transplantation 40%
• Etoposide 20%
• Complete Remission 20%
• Induction Therapy 20%
• Remission 20%
• Bone Marrow Failure 20%
• Maintenance Therapy 20%
• Central Nervous System Relapse 20%
• Bone Marrow Relapse 20%
• Bacterial Sepsis 20%
• Bolus 20%
• Granulocyte Colony-stimulating Factor (G-CSF) 20%
• Fungal Sepsis 20%
• Heavily Pretreated 20%
• Ifosfamide 20%
• Moderate Activity 20%

Medicine and Dentistry

• Cytarabine 100%
• Acute Lymphoblastic Leukemia 100%
• Childhood Cancer 100%
• Idarubicin 100%
• Bone Marrow Transplantation 40%
• Infusion 20%
• Etoposide 20%
• Central Nervous System 20%
• Maintenance Therapy 20%
• Granulocyte Colony Stimulating Factor 20%
• Ifosfamide 20%
• Bone Marrow Disease 20%
• Fungemia 20%
• Adolescence 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Acute Lymphoblastic Leukemia 100%
• Cytarabine 100%
• Idarubicin 100%
• Childhood Cancer 100%
• Remission 40%
• Etoposide 20%
• Bone Marrow Disease 20%
• Fungemia 20%
• Ifosfamide 20%
• Granulocyte Colony Stimulating Factor 20%